Orion Oyj (OTCMKTS:ORINY) Sees Large Growth in Short Interest

Orion Oyj (OTCMKTS:ORINY) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 500 shares, a growth of 66.7% from the January 31st total of 300 shares. Based on an average trading volume of 1,000 shares, the days-to-cover ratio is currently 0.5 days.

Orion Oyj Stock Performance

ORINY traded up $0.49 on Tuesday, reaching $28.63. The stock had a trading volume of 946 shares, compared to its average volume of 3,498. The business’s 50-day moving average price is $25.19 and its two-hundred day moving average price is $25.23. The company has a market cap of $8.08 billion, a P/E ratio of 22.72 and a beta of 0.25. Orion Oyj has a 12-month low of $17.50 and a 12-month high of $28.63. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25.

Orion Oyj (OTCMKTS:ORINY) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. The firm had revenue of $463.41 million during the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. Sell-side analysts forecast that Orion Oyj will post 1.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Nordea Equity Research cut shares of Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.